Anti-Human 4-1BB Recombinant Antibody (Urelumab) (CAT#: TAB-179)

Recombinant monoclonal antibody to 4-1BB. Urelumab (ue rel' ue mab; also known as BMS-663513 and anti-4-1BB antibody) is a fully human IgG4 monoclonal antibody for the treatment of cancer and solid tumors.
Urelumab targets the CD137 receptor. It specifically binds to and activates CD137-expressing immune cells, stimulating an immune response, in particular a cytotoxic T cell response, against tumor cells.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Tested Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA

Figure 1 Administration of anti-hPD-1 mAb (nivolumab) as a single agent or in combination with anti-hCD137 (urelumab) exacerbates xGVHD mediated by human PBMCs in Rag2−/−IL2Rγnull mice.

Figure 1 Administration of anti-hPD-1 mAb (nivolumab) as a single agent or in combination with anti-hCD137 (urelumab) exacerbates xGVHD mediated by human PBMCs in Rag2−/−IL2Rγnull mice.

A, Rag2−/−IL2Rγnull mice were injected with 107 human PBMCs i.p. on day 0. Treatments with anti-hCD137 (urelumab), anti-hPD-1 (nivolumab), combination (Combo; urelumab+nivolumab), or saline control i.v. were injected on days 4, 7, and 10. Survival was monitored up to 100 days. B, the Kaplan–Meier plot depicts overall survival among the four groups of treatment urelumab (n = 22), nivolumab (n = 23), combination (Combo; n = 13), and control (n = 19). Experiments were independently repeated three times and results pooled. *, P < 0.5; ***, P < 0.001. C, microphotographs of H&E and hCD3 IHC stainings in representative tissue sections of spleen, liver, and lung in one representative mouse from each group of treatment. Bar, 400 μm.

Sanmamed, M. F., Rodriguez, I., Schalper, K. A., Onate, C., Azpilikueta, A., Rodriguez-Ruiz, M. E., ... & Alfaro, C. (2015). Nivolumab and urelumab enhance antitumor activity of human T lymphocytes engrafted in Rag2−/− IL2Rγnull immunodeficient mice. Cancer research.

Figure 2 Evidence for enhanced xenoreactive human lymphocyte activity upon treatment with anti-hCD137 (urelumab), anti-hPD-1 (nivolumab), and their combination.

Figure 2 Evidence for enhanced xenoreactive human lymphocyte activity upon treatment with anti-hCD137 (urelumab), anti-hPD-1 (nivolumab), and their combination.

Experiments performed as in Fig. 2A. A, human IFNγ plasma levels of mice were studied before the first mAb dose and after the first (day 6) and second (day 9) doses of antibodies. B and C, mice were sacrificed at week 3 after human PBMCs transfer and single-cell suspensions were prepared from the lung, liver, spleen, and peritoneal lavage to be studied by flow cytometry. B, absolute numbers of hCD3+ (right) and hCD8+ (left) per gram of tissue in the liver. C, perforin mean fluorescence intensity (MFI) of hCD3+hCD8+ (left) and hCD3+hCD4+ (right) in the lung lymphocyte infiltrates. Data were analyzed by the Mann–Whitney U test. *, P < 0.05; **, P < 0.01. Error bars represent SEM.

Sanmamed, M. F., Rodriguez, I., Schalper, K. A., Onate, C., Azpilikueta, A., Rodriguez-Ruiz, M. E., ... & Alfaro, C. (2015). Nivolumab and urelumab enhance antitumor activity of human T lymphocytes engrafted in Rag2−/− IL2Rγnull immunodeficient mice. Cancer research.

Figure 3 Immunostimulatory mAbs anti-hCD137 (urelumab) and anti-hPD-1 (nivolumab) alone or in combination show antitumor activity against a xenografted human colon cancer mediated by transferred allogeneic human PBMC.

Figure 3 Immunostimulatory mAbs anti-hCD137 (urelumab) and anti-hPD-1 (nivolumab) alone or in combination show antitumor activity against a xenografted human colon cancer mediated by transferred allogeneic human PBMC.

A, Rag2−/−IL2Rγnull mice were injected with 7 × 106 human PBMCs i.p. and challenged with 3.5 × 106 HT-29 cells s.c. in the right flank on day 0 of the experiment. Thereafter, the mice were treated with anti-hCD137 (urelumab), anti-hPD-1 (nivolumab), combination (urelumab+nivolumab), or isotype control (hIgG4) i.v. on days 6, 14, and 20. Tumor volumes were measured twice per week until mice were sacrificed on day 22 of experiment. Tumors were removed after sacrifice and studied by flow cytometry and IHC. B, results depict mean ± SEM of the progression of subcutaneous tumor volumes (n = 5 mice per group). Arrows, time of treatment administration. Experiments were repeated four times, rendering similar results. C, human IFNγ plasma levels were studied previous to the first mAb dose, after the first and second antibody dose. D, tumor TILs from each treatment group were studied by flow cytometry and results of number of human CD8 T lymphocytes per mg of tumor (left), number of human regulator T cells per gram of tumor (center graph), and ratio of number of human CD8 T cells per number of human Treg (right) are depicted. *, P < 0.05; **, P < 0.01. Error bars represent SEM. T, tumor; p< hPBMCs.

Sanmamed, M. F., Rodriguez, I., Schalper, K. A., Onate, C., Azpilikueta, A., Rodriguez-Ruiz, M. E., ... & Alfaro, C. (2015). Nivolumab and urelumab enhance antitumor activity of human T lymphocytes engrafted in Rag2−/− IL2Rγnull immunodeficient mice. Cancer research.

Figure 4 hCD137, hPD-1, and PD-L1/B7-H1 are expressed in the xenografted tumors.

Figure 4 hCD137, hPD-1, and PD-L1/B7-H1 are expressed in the xenografted tumors.

Representative multiplexed immunofluorescence microphotographs showing the protein expression of hCD137 (red fluorescence channel, left), hPD-1 (red channel, middle), and PD-L1 (red channel, right) in the tumor tissues (cytokeratin positive, green channel) from mice subjected to treatment with hIgG4 (control), anti-hCD137 (urelumab), anti-hPD-1 (nivolumab), or the combination (Combo). hCD137 and hPD-1 positivity was distributed predominantly toward the periphery of the tumor surrounding the cytokeratin-positive tumor areas. In contrast, PD-L1 was allocated predominantly toward the tumor center/core, in close association with the tumor nests. Nuclei were stained with DAPI (blue fruorescence channel). Bar, 100 μm.

Sanmamed, M. F., Rodriguez, I., Schalper, K. A., Onate, C., Azpilikueta, A., Rodriguez-Ruiz, M. E., ... & Alfaro, C. (2015). Nivolumab and urelumab enhance antitumor activity of human T lymphocytes engrafted in Rag2−/− IL2Rγnull immunodeficient mice. Cancer research.


Specifications

  • Immunogen
  • Ectodomain of human 4-1BB recombinant protein.
  • Host Species
  • Human
  • Derivation
  • Human
  • Type
  • IgG4 - kappa
  • Specificity
  • Tested positive against native human antigen.
  • Species Reactivity
  • Human
  • Applications
  • ELISA, FC, IP, FuncS, IF, Neut, ICC
  • CAS
  • 934823-49-1
  • Generic Name
  • Urelumab
  • MW
  • 145.8 kDa
  • Related Disease
  • Tumors

Product Property

  • Purity
  • Purity >95% by SDS-PAGE.
  • Storage
  • At -20°C for one year.

Applications

  • Application Notes
  • The TNFRSF9 antibody has been reported in applications of H&E staining, Activ, Stim, IF.

Target

  • Alternative Names
  • Urelumab;934823-49-1;BMS-663513;BMS-663513;TNFRSF9;tumor necrosis factor receptor superfamily, member 9;ILA;tumor necrosis factor receptor superfamily member 9;4 1BB;CD137;CD137 antigen;T cell antigen ILA;T-cell antigen ILA;4-1BB ligand receptor;homolog o

Related Resources

  • Biosimilar Overview
Please refer to Urelumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Urelumab.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Urelumab"

Afuco™ Anti-TNFRSF9 ADCC Recombinant Antibody (Urelumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to 4-1BB. Urelumab (ue rel' ue mab; also known as BMS-663513 and anti-4-1BB antibody) is a fully human IgG4 monoclonal antibody for the treatment of cancer and solid tumors.
Urelumab targets the CD137 receptor. It specifically binds to and activates CD137-expressing immune cells, stimulating an immune response, in particular a cytotoxic T cell response, against tumor cells.

See other products for "TNFRSF9"

Immunotoxin

CAT Product Name Application Type
AGTO-G063S Anti-TNFRSF9 immunotoxin (scFv)-Sap Cytotoxicity assay, Function study

Fc Glycosylation

High-mannose Glycoform

Blocking Antibody

Neutralizing Antibody

CAT Product Name Application Type
NEUT-2169CQ Rat Anti-Tnfrsf9 Recombinant Antibody (clone 6J43) Neut, WB Rat IgG2

Human Antibody

CAT Product Name Application Type
TAB-457CQ Anti-Human TNFRSF9 Recombinant Antibody (Utomilumab) ELISA, IHC, FC, IP, IF, FuncS IgG2, λ

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-457CQ Afuco™ Anti-TNFRSF9 ADCC Recombinant Antibody (Utomilumab), ADCC Enhanced ELISA, IHC, FC, IP, IF, FuncS ADCC enhanced antibody
AFC-TAB-179 Afuco™ Anti-TNFRSF9 ADCC Recombinant Antibody (Urelumab), ADCC Enhanced ELISA, FC, IP, FuncS, IF, Neut ADCC enhanced antibody

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for TAB-179. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare